Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Volume Increase – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw unusually-high trading volume on Tuesday . Approximately 7,101 shares traded hands during trading, an increase of 92% from the previous session’s volume of 3,696 shares.The stock last traded at $44.03 and had previously closed at $49.75.

Analysts Set New Price Targets

ZLDPF has been the topic of several research reports. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Finally, William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The firm has a 50 day simple moving average of $47.99 and a 200-day simple moving average of $59.11. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.03 billion, a PE ratio of 3.14 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The company had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. As a group, research analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.